A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
09/2011
09/22/2011	WO2011115562A1 Antimicrobial compound
09/22/2011	WO2011115246A1 Ebna1 function inhibitor
09/22/2011	WO2011115183A1 Novel monocyclic pyrimidine derivative
09/22/2011	WO2011115065A1 Cyclopropanecarboxylic acid derivative
09/22/2011	WO2011115064A1 Cycloalkyl-substituted imidazole derivative
09/22/2011	WO2011114346A1 Chitin and related compounds for use in treating bacterial and viral infections
09/22/2011	WO2011114137A1 Toluidine blue derivatives as photosensitising compounds
09/22/2011	WO2011113981A1 Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids
09/22/2011	WO2011113606A1 Anti-infective compounds
09/22/2011	WO2011113578A1 New oxadiazole derivatives
09/22/2011	WO2011113361A1 Ceftizoxime sodium crystalline hydrate, preparation methods and uses thereof
09/22/2011	WO2011113190A1 Pharmaceutical composition for treating aids and preparation method thereof
09/22/2011	WO2011113160A1 Bacterial vaccine components from staphylococcus aureus and uses thereof
09/22/2011	WO2011086575A3 A pharmaceutical composition for treatment respiratory tract infections
09/22/2011	WO2011056545A3 Antimicrobial ionic liquids
09/22/2011	WO2011053798A3 Peptide compositions and methods for inhibiting herpesvirus infection
09/22/2011	WO2011049979A3 Injectable formulations for intra- articular or peri-articular administration
09/22/2011	WO2011049908A3 Bismacrokyclic compounds as hepatitis c virus inhibitors
09/22/2011	WO2011049348A3 Antiviral agents obtained from curcuma longa, having inhibitory activities against avian influenza, swine influenza, and novel influenza
09/22/2011	WO2011025982A3 Tetracycline compounds
09/22/2011	US20110230637 Modified human thymic stromal lymphopoietin
09/22/2011	US20110230571 Diagnostic and therapeutic protocols
09/22/2011	US20110230560 Synergetic composition comprising flavouring substances and organic acids and use thereof
09/22/2011	US20110230558 Use of cationic surfactants for the inactivation of toxins
09/22/2011	US20110230554 Method of Treating Viral Infections by Administration of Ethyl Mercury or Thiol Derivative Thereof
09/22/2011	US20110230550 Compounds, compositions and methods
09/22/2011	US20110230546 dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION
09/22/2011	US20110230544 Modulation of c-reactive protein expression
09/22/2011	US20110230533 Imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use
09/22/2011	US20110230524 Substituted 2-(5-hydroxy-2-methyl-1h-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases
09/22/2011	US20110230523 Transcription factor modulating compounds and methods of use thereof
09/22/2011	US20110230515 Compounds and methods for treatment and prevention of diseases
09/22/2011	US20110230489 s-TRIAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME
09/22/2011	US20110230483 Pyridine and Pyrazine derivative for the Treatment of CF
09/22/2011	US20110230474 Topical antimicrobial compositions and methods of using same
09/22/2011	US20110230470 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors
09/22/2011	US20110230465 Viral polymerase inhibitors
09/22/2011	US20110230464 Purine derivatives useful as p13 kinase inhibitors
09/22/2011	US20110230452 Compounds and methods for the treatment of pain and other diseases
09/22/2011	US20110230451 Identification and use of compounds that affect the fidelity of eukaryotic translation initiation codon selection
09/22/2011	US20110230436 Uracyl Cyclopropyl Nucleotides
09/22/2011	US20110230432 Compositions and kits for treating influenza
09/22/2011	US20110230431 Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections
09/22/2011	US20110230397 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
09/22/2011	US20110230396 Anti-infective compounds and uses thereof
09/22/2011	US20110230393 Antibacterial Phage Peptides and Methods of Use thereof
09/22/2011	US20110229584 Compound for the control of herpes simplex virus using glycyrrhizic acid, lipoic acid, allantoin, and slippery elm
09/22/2011	US20110229583 Human Medicinal Treatment Typically Using Salt of Peroxymonosulfuric Acid
09/22/2011	US20110229581 Releasable cationic lipids for nucleic acids delivery systems
09/22/2011	US20110229574 Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
09/22/2011	US20110229573 Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
09/22/2011	US20110229565 Drug Delivery Composition Comprising a Self-Assembled Gelator
09/22/2011	US20110229560 Nlrc5 as a target for immune therapy
09/22/2011	US20110229551 Drug delivery compositions and methods using nanofiber webs
09/22/2011	US20110229550 Acid-Degradable and Bioerodible Modified Polyhydroxylated Materials
09/22/2011	US20110229544 Methods for Inhibiting Gram-Postive Bacteria Using Non-Phospholipid Lipid Vesicules
09/22/2011	US20110229539 Chewing gum possessing tooth cleaning effect and a teeth cleaning method
09/22/2011	US20110229536 Compositions for topical application comprising microencapsulated colorants
09/22/2011	US20110229522 Methods, compositions and vaccines relating to neisseria meningitidis antibodies
09/22/2011	US20110229519 Vaccine composition for use against influenza
09/22/2011	US20110229518 Optimized influenza vaccines
09/22/2011	US20110229517 System and process for producing multi-component biopharmaceuticals
09/22/2011	US20110229515 Identification of genes
09/22/2011	US20110229513 LPS Based Vaccines
09/22/2011	US20110229512 Compositions and methods for diagnosing and treating urinary tract infections
09/22/2011	US20110229509 Polypeptides for inducing a protective immune response against staphylococcus aureus
09/22/2011	US20110229508 Polypeptides for inducing a protective immune response against staphylococcus aureus
09/22/2011	US20110229507 Stable anthrax vaccine formulations
09/22/2011	US20110229503 Vaccination against malignant melanoma using bcg and/or vaccinia
09/22/2011	US20110229502 Ablative immunotherapy
09/22/2011	US20110229496 Method for regulating survival and memory of t helper 1 cells
09/22/2011	US20110229490 Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies
09/22/2011	US20110229488 Progastrin and liver pathologies
09/22/2011	US20110229486 Monoclonal Antibodies Against NKG2A
09/22/2011	US20110229484 Host Cell Kinases as Targets for Antiviral Therapies Against HCV Infection
09/22/2011	US20110229482 Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood by preventing viral entry into a cell
09/22/2011	US20110229477 Methods for Treatment of HIV and Other Infections Using a T Cell or Viral Activator and Anti-Retroviral Combination Therapy
09/22/2011	US20110229476 Monospecific and multispecific antibodies and method of use
09/22/2011	US20110229474 Monitoring and inhibiting human immunodeficiency virus infection by modulating hmgb1 dependent triggering of hiv-1 replication and persistence
09/22/2011	US20110229466 Vascular endothelial growth factor 2
09/22/2011	US20110229461 PD-1 Antibodies
09/22/2011	US20110229457 Injectable drug delivery system
09/22/2011	US20110229438 Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
09/22/2011	US20110229437 Method of Treating Asthma with Antiviral Agents
09/22/2011	US20110229435 Expression and purification of hip/pap and uses therefor
09/22/2011	US20110229423 Pacap signaling pathway modulators for treating inflammatory skin diseases having a neurogenic component, notably rosacea, and compositions comprised thereof
09/22/2011	US20110229409 Linkable lewis x analogs
09/22/2011	US20110229407 Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof
09/22/2011	DE102010012232A1 New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases
09/22/2011	CA2797295A1 Ganglioside micelles as a delivery system for hidrophobic drugs
09/22/2011	CA2793523A1 Cyclopropanecarboxylic acid derivative
09/22/2011	CA2793086A1 Anti-infective compounds
09/22/2011	CA2792956A1 Bacterial vaccine components from staphylococcus aureus and uses thereof
09/22/2011	CA2791505A1 Cycloalkyl-substituted imidazole derivative
09/21/2011	EP2366774A2 PUFA polyketide synthase systems and uses thereof
09/21/2011	EP2366773A2 PUFA polyketide synthase systems and uses thereof
09/21/2011	EP2366772A2 PUFA polyketide synthase systems and uses thereof
09/21/2011	EP2366771A2 PUFA polyketide synthase systems and uses thereof
09/21/2011	EP2366707A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
09/21/2011	EP2366702A1 New oxadiazole derivatives

1 ... 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 ... 1798